The Impact of Abdominal Wall Closure Technique on Incidence of Incisional Hernia in Kidney Transplantation

Overview

STUDY SUMMARY Incisional hernias, or swellings of the abdominal scar after surgery, remain problematic especially after transplant surgery. This is because they can cause complications, including trapping of bowel or the transplant. This can cause life threatening emergencies but is at the very least unsightly and uncomfortable for the patient. Transplant patients are especially likely to develop hernias because of the diseases causing the renal failure and the drugs that they take to dampen the immune system. There is evidence from other surgery that the stitching methods that are used to close the wounds might decrease the risk of surgical hernias. This is achieved by placing smaller and more numerous sutures (stitches) in the wound to increase the strength of the repair. However, this has never been tested formally in transplant where it may provide significant benefit. We intend to do some initial investigation of whether using the smaller stitches may provide benefit over more traditional methods that are currently being used. We will look at early complications after surgery but also the rate of hernia formation later. We hope to improve outcomes and reduce complications for our transplant patients by doing this. In addition we will collect blood and tissue samples from both live kidney donors and the recipients to microscopically analyse their collagen to identify potential factors which may indicate risk of hernia formation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2023

Detailed Description

Study Design This study has two phases. In phase 1 we will perform a retrospective review of hernia incidence in our centre over the last decade. We will seek to identify risk factors in our transplant cohort. In phase 2 we will perform a prospective randomised blinded feasibility trial in which the conventional large bites technique will be compared with the small bites technique. STUDY SETTING The study will be carried out on one site at Manchester Royal Infirmary, part of Manchester University National Health Service (NHS) Foundation Trust. This is a regional Renal and Pancreas Transplant centre performing approximately 60 pancreas transplants per annum and 350 kidney transplants. All members of the team have academic track records and participate in several on-going research projects. Current research projects are investigating cardiovascular disease, kidney perfusion, Magnetic Resonance (MR) imaging to name a few. RESEARCH QUESTIONS, AIMS, AND OBJECTIVES Phase 1 To retrospectively evaluate the incidence of incisional hernias in our transplant population and associated risk factors. Phase 2 1. To perform prospective randomized double blinded feasibility trial to investigate the use of "small bites" (SB) vs "large bites (LB)" for closure of abdominal incisions following kidney transplantation. 2. To collect detailed medical histories from all patients included in the study to look for potential medical risk factors which may predispose to hernia formation. 3. To collect tissue and blood samples to investigate potential biological and histological markers of hernia formation, from both patients with end stage renal failure receiving a living-donor kidney transplant, and samples from the donor nephrectomy patients for histological comparison. 4. To assess quality of life and pain scores in the early and delayed post-operative phase (week 1, 6 months and 1 year) Outcomes Phase 1 Incidence of Incisional Hernia within 1 and 3 years post-transplant clinically or radiologically detected. Phase 2 Primary outcome Incidence of Incisional Hernia within one year post transplant, either clinically or radiologically detected. Any incisional hernia identified will be classified as per European Hernia Society Guidelines. Secondary outcomes Incidence of post-operative complications at 6 months post op (burst abdomen, chest infection, surgical site infection returns to theatre,etc), pain score, costs, length of hospital stay, quality of life at week 1, 6 and 12 months post-transplant, collagen and serum biomarkers which may predispose to hernia formation Sampling and recruitment Sample identification Phase 1 Data will be collected from the medical records of our Transplant population and entered into an excel spreadsheet no personal identifiers will be recorded. Phase 2 The Chief Investigator (CI) and Principle Investigator (PI) will identify patients on the transplant waiting list and send copies of the information sheet. Following ethical approval, patients undergoing first or second renal transplantation will be asked for informed consent to participate in the study to receive either small or large bites. The CI and PI are part of the direct care team. The CI will have custody of the clinical information. Clinical details will be recorded on hospital pass worded computers. Blood samples will be anonymised at the time of collection. Patients will be given a study code and blood samples will be labelled with this code to ensure anonymity. The custodian of the data and samples will be the CI.Mr David van Dellen.

Interventions

  • Procedure: Small stitch
    • Wound closure will be using small stiches or larger spaced stitches
  • Other: Blood sample
    • A blood sample to look for biological markers of Hernia formation will be taken
  • Other: Tissue Sample
    • A tissue sample will be taken to measure markers of wound healing.
  • Other: Pain Score
    • A pain score will be recorded following the surgical procedure.
  • Other: Quality of Life Score
    • A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery

Arms, Groups and Cohorts

  • Active Comparator: Small Stitch
    • Small stitch for wound closure
  • Active Comparator: Large Stitch
    • Large Stitch for wound closure

Clinical Trial Outcome Measures

Primary Measures

  • Hernia
    • Time Frame: 1 year
    • Incidence of Incisional Hernia within one year post transplant, either clinically or radiologically detected. Any incisional hernia identified will be classified as per European Hernia Society Guidelines.

Secondary Measures

  • Number of Complications
    • Time Frame: 1 year
    • Incidence of post-operative complications at 6 months post op (burst abdomen, chest infection, surgical site infection, returns to theatre).
  • Pain Scores
    • Time Frame: 1 week 6 months and 12 months
    • The level of pain as assessed by a pain score.
  • Length of Stay in Hospital following surgery
    • Time Frame: Number of days in hospital in 12 months post operation
    • The number of days in hospital
  • Quality of Life Post surgery
    • Time Frame: 1 week 6 months 12 months post surgery
    • A quality of life questionnaire will be administered.

Participating in This Clinical Trial

Inclusion Criteria

  • End-stage renal failure patients – Aged 18-70yrs – First transplants or second transplants – Ability to adequately understand English and consent for study – BMI<35 kg/m2) – Living donor nephrectomy patients Exclusion Criteria – Outside age range, – Previous transplants which have left a scar in the ilia fossa

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Manchester University NHS Foundation Trust
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Alex Shaw, +441617012066, alex.shaw@mft.nhs.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.